Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.54 |
| ▸ | HPGD | P15428 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18995944 | 0.84 | KDM4E (0.52) | KDM4EALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL21099837 | 0.84 | KDM4E (0.52) | KDM4EALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL19764530 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL8352732 | 0.81 | KDM4E (0.59) | KDM4EALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL9946224 | 0.78 | KDM4E (0.56) | KDM4EALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL2813856 | 0.77 | KDM4E (0.58) | KDM4EALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL9597409 | 0.77 | KDM4E (0.58) | KDM4EALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL12309221 | 0.77 | KDM4E (0.58) | KDM4EALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL9569958 | 0.77 | KDM4E (0.58) | KDM4EALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL9944492 | 0.77 | KDM4E (0.55) | KDM4EALDH1A1HPGDNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3247705-B1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF AS NAMPT INHIBITORS | MILLENNIUM PHARM INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NAMPT, NQO2, NNMT | KDM4E 416/4885ALDH1A1 1374/4885HPGD 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.